Imunohematologia veterinária: antígenos eritrocitários caninos / Veterinary immunohematology: canine erythrocyte antigen / Inmunohematología veterinaria: antígenos eritrocitarios caninos

A imunohematologia veterinária vem ganhando interesse nos últimos anos devido a maior acessibilidade a tecnologias de detecção de antígenos e anticorpos, interesse dos donos e médicos veterinários em buscar uma melhor qualidade de vida para os animais e as necessidades de transfusões com o menor índice possível de reações indesejadas. Os cães possuem antígenos presentes na membrana de suas células vermelhas, podendo causar reações durante e após transfusões. Diferentemente de humanos e felinos, cães não possuem anticorpos naturais para os principais antígenos, a priori podendo ser transfundidos com qualquer tipo sanguíneo sem consequências posteriores, porém, se submetidos a uma segunda transfusão, sendo essa de um tipo sanguíneo incompatível e previamente sensibilizados, as chances de ocorrer reações transfusionais graves aumentam drasticamente, ocasionando danos ao animal, podendo levá-lo à morte. Por conta desses riscos se faz necessário uma maior atenção aos tipos sanguíneos desses animais onde 8 sistemas são reconhecidos internacionalmente classificados como sistema DEA, sendo eles DEA 1 e seus subtipos (DEA 1.1; DEA1.2; DEA 1.3); DEA 3; DEA 4; DEA 5; DEA 6; DEA 7 e DEA 8, e recentemente um novo sistema denominado Dal. Não há disponível ainda soros para os sistemas DEA 6 e DEA 8, tornando a pesquisa sobre esses antígenos dificultosa.(AU)

Veterinary immunohematology is gaining interest in recent years due to greater accessibility to antigen and antibody detection technologies, the interests of pet owners and veterinarians in seeking a better quality of life for animals, and requirement of transfusions with the lowest possible rate of collateral reactions. Dogs have antigens present in the membrane of their red blood cells that can cause reactions during and after transfusions. Unlike humans and cats, dogs do not have natural antibodies to the key antigens, and a priori they can be transfused with any type of blood without any further consequences. However, if they are ever subjected to a second transfusion, if using incompatible blood types and being previously sensitized, the likelihood of having serious transfusion reactions drastically increase, causing damage to the animal, which may even lead it to death. Due to those risks, greater attention is required to the blood type of those animals, which present 8 systems, internationally recognized and classified as the DEA system, namely DEA 1 and its subtypes (DEA 1.1; DEA 1.2; DEA 1.3); DEA 3; DEA 4; DEA 5; DEA 6; DEA 7 and DEA 8, and recently a new system referred to as Dal. No serum is yet available for DEA 6 and DEA 8 systems, hindering the research on those antigens.(AU)

La inmunohematología veterinaria ha ganado atención en los últimos años debido mayor accesibilidad a tecnologías de detección de antígenos y anticuerpos, interés de dueños y médicos veterinarios en buscar mejor calidad de vida para los animales y las necesidades de transfusiones con menor índice posible de reacciones indeseadas. Los perros poseen antígenos presentes en la membrana de sus células rojas, pudiendo causar reacciones durante y después de transfusiones. Diferentemente de humanos y felinos, perros no tienen anticuerpos naturales para los principales antígenos, a priori, pudiendo ser transfundidos con cualquier tipo de sangre sin consecuencias posteriores, todavía, si sometidos a una segunda transfusión, siendo esa de un tipo sanguíneo incompatible y previamente sensibilizados, la posibilidad de ocurrir reacciones transfusional grave aumenta drásticamente, ocasionando daños al animal, pudiendo llevarlo a la muerte. Por esos riesgos se hace necesario más atención a los tipos sanguíneos de esos animales, donde 8 sistemas son reconocidos internacionalmente y clasificados como sistema DEA, siendo ellos DEA 1 y sus subtipos (DEA 1.1; DEA 1.2; DEA 1.3); DEA 3; DEA 4; DEA 5; DEA 6; DEA 7 y DEA 8, y recién un nuevo sistema denominado Dal. No hay aún disponible sueros para los sistemas DEA 6 y DEA 8, haciendo dificultosa la investigación sobre esos antígenos.(AU)

Lack of association between alopecia areata and HLA class I and II in a southeastern Brazilian population

Abstract: Background: Alopecia areata (AA) is a common disorder of unknown etiology that affects approximately 0.7% to 3.8% of patients among the general population. Currently, genetic and autoimmune factors are emphasized as etiopathogenic. Studies linking Human Leukocyte Antigens (HLA) to AA have suggested that immunogenetic factors may play a role in the disease's onset/development. Objectives: To investigate an association between AA and HLA class I/II in white Brazilians. Methods: Patients and control groups comprised 33 and 112 individuals, respectively. DNA extraction was performed by column method with BioPur kit. Allele's classification was undertaken using the PCR-SSO technique. HLA frequencies were obtained through direct counting and subjected to comparison by means of the chi-square test. Results: Most patients were aged over 16, with no familial history, and developed partial AA, with no recurrent episodes. Patients showed a higher frequency of HLA-B*40, HLA-B*45, HLA-B*53 and HLA-C*04 compared with controls, although P was not significant after Bonferroni correction. Regarding HLA class II, only HLA-DRB1*07 revealed statistical significance; nevertheless, it featured more prominently in controls than patients (P=0.04; Pc=0.52; OR=0.29; 95%; CI=0.07 to 1.25). P was not significant after Bonferroni correction. Conclusions: The development of AA does not seem to be associated with HLA in white Brazilians, nor with susceptibility or resistance. The studies were carried out in populations with little or no miscegenation, unlike the Brazilian population in general, which could explain the inconsistency found.

43 kDa and 66 kDa, two blood stage antigens induce immune response in Plasmodium berghei malaria.

The hunt for an effective vaccine against malaria still continues. Several new target antigens as candidates for vaccine design are being explored and tested for their efficacy. In the present study the sera from mice immunized with 24,000 × g fraction of Plasmodium berghei has been used to identify highly immunogenic blood stage antigens. The protective antibodies present in immune sera were covalently immobilized on CNBr activated sepharose 4B and used for affinity chromatography purification of antigens present in blood stages of P. berghei. Two polypeptides of 66 and 43 kDa molecular weights proved to be highly immunogenic. They exhibited a strong humoral immune response in mice as evident by high titres in ELISA and IFA. Protective immunity by these two antigens was apparent by in vivo and in vitro studies. These two proteins could further be analysed and used as antigens in malaria vaccine design.